Sarepta Therapeutics’ report of a second fatality this year in a patient dosed with its Duchenne muscular dystrophy gene therapy raised the prospect it might have to pull the product from the market.

Talkiatry, a telepsychiatry company, has secured $130 million in Series C funding, which the company will use for growth and advancing value-based care, it announced on Tuesday. New York City-based ...

Novartis has made kidney disorders an area of focus, and it’s now adding a new drug prospect through a deal to acquire Regulus Therapeutics, a biotech with a drug ready for pivotal testing in a rare ...

Function Health — the platform that gives subscribers access to more than 160 different lab tests — closed a $298 million Series B funding round on Wednesday, bringing the startup’s valuation to $2.5 ...

Turquoise Health raised $40 million in a Series C round to expand beyond price transparency into managing healthcare ...

Stryker was hit by a cyberattack this week that knocked out its internal systems worldwide and caused delays to order ...

Universal Health Services plans to acquire Talkspace for $835 million to create a national behavioral health platform that ...

Employer groups praised a bill aimed at boosting healthcare competition and lowering costs by banning anticompetitive insurer-provider contracts.

GuardDog Telehealth admitted it misrepresented its services to access patients’ health information, marking the first major concession in Epic’s lawsuit against Health Gorilla and other defendants ...

This week, health data platform Arcadia made an acquisition that CEO Michael Meucci thinks will give the Boston-based company the data it needs to offer a more comprehensive suite of value-based care ...

Over the past month, two large provider organizations have announced partnerships with Reimagine Care, a Nashville-based startup focused on providing support to cancer patients who are in active ...

AbbVie has inflammatory bowel disease covered with blockbuster drugs now on the market and additional drug candidates in clinical development. The pharmaceutical giant is diversifying its IBD ...